Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21080214 | 1.00 | SMYD3 (0.40) | SMYD3NPC1RAB9ASTAT3TSHR | |
| SCHEMBL21162012 | 0.82 | KDM1A (0.42) | — | |
| SCHEMBL23536110 | 0.75 | SCD5 (0.38) | NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL19715241 | 0.70 | NPC1 (0.76) | SMYD3NPC1RAB9A | |
| SCHEMBL17592584 | 0.70 | NPC1 (0.76) | SMYD3NPC1RAB9A | |
| SCHEMBL3274985 | 0.69 | MAPK14 (0.49) | SMYD3NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL21490677 | 0.67 | POLB (0.38) | SMYD3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21490729 | 0.67 | POLB (0.38) | SMYD3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2586465 | 0.67 | SMN1; SMN2 (0.46) | NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL3590347 | 0.66 | HCAR2 (0.50) | SMYD3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | SMYD3 4410/4885NPC1 3103/4885RAB9A 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.